Effect of membrane composition on cytokine production and clinical symptoms during hemodialysis: A crossover study

Renal Failure

Volumn 25, Issue 3, 2003, Pages 419-430

  Singh, N P ^a   Bansal, Ravi ^a   Thakur, A ^a   Kohli, R ^a   Bansal, R C ^a   Agarwal, S K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Biocompatibility; Cytokines; Dialysis membrane; Intradialytic symptoms

Indexed keywords

ANTICOAGULANT AGENT; CYTOKINE; HEPARIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS; DIALYSIS MEMBRANE; HEMODIALYSIS; HUMAN; IMMUNE RESPONSE; KIDNEY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; CELLULOSE; CROSS-OVER STUDIES; CYTOKINES; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION, RENAL; INTERLEUKIN-1; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYCYSTIC KIDNEY DISEASES; POLYMERS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; STATISTICS; SULFONES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037640042     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120021154     Document Type: Article

References (35)

1. Lipps, B.; Stewart, R.; Perkins, H. The hollow fiber artificial kidney. Trans. Am. Soc. Artif. Intern. Organs 1967, 13, 200-207.
2. Walton, D.; Cheung, A. Membrane biocompatibility. In Clinical Dialysis, 3; Nissenson, A., Fine, R., Gentile, D., Norwalk, C.T., Eds.; Appleton and Lange, 1995; 93-120.
3. Colton, CK. Analysis of membrane processes for blood purification. Blood Purif. 1987, 5 (4), 202-251.
4. Henderson, L.W.; Koch, K.M.; Dinarello, C.A.; Shaldon, S. Hemodialysis hypotension the interleukin hypothesis. Blood Purif. 1983, 1, 3-8.
5. Gesualdo, L.; Pertosa, G.; Grandaliano, G.; Schena, F.P. Cytokines and bioincompatibility. Nephrol. Dial. Transplant. 1998, 13 (7), 1622-1626.
6. Jorres, A.; Froese, P.; Fischer, C.; Safak, H.; Gahl, G.M.; Muller, C.; Vienken, J. Variables associated with the assessment of systemic tumor necrosis factor alpha levels during hemodialysis. Int. J. Artif. Organs 1992, 15 (11), 653-657.
7. Pollak, V.E.; Charoenpanich, R.; Robson, M.; Kant, K.S. Dialyzer membranes: syndromes associated with first use and effects of multiple use. Kidney Int. suppl. 1988, 24, S49-S52.
8. Hakim, R.M. Influence of the dialysis membrane on outcome of ESRD patients. Am. J. Kidney Dis. 1998, 32 (6 suppl 4), S71-75.
9. Klinkmann, H.; Vienken, J. Membranes for dialysis. Nephrol. Dial. Transplant. 1995, 10 (suppl 3), 39-45.
10. Gardinali, M.; Calcagno, A.; Conciato, L.; Agostoni, A.; Rosti, A.; Cori, P.; Vozzo, N.; Moroni, A.; Anelli, A.; Zoni, U. Complement activation in dialysis: effects on cytokines, lymphocyte activation and beta 2 microglobulin. Int. J. Artif. Organs 1994, 17 (6), 337-344.
11. Dunati, D.; Degiannis, D.; Homer, L.; Raska, K. Jr.; Roskova, J. Production and kinetics of interleukin-1 in hemodialysis. In vivo and in vitro study. Am. J. Nephrol. 1991, 11 (6), 451-458.
12. Herbelin, A.; Urena, P.; Nguyen, A.T.; Zingraff, J.; Descamps-Latscha, B. Influence of first and long term dialysis on uremia associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol. Dial. Transplant 1991, 6 (5), 349-357.
13. Herbelin, A.; Nguyen, A.T.; Zingraff, J.; Urena, P.; Deschamps-Latsha, B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumour necrosis factor alpha. Kidney Int. 1990, 37, 116-125.
14. Pereira, B.J.; Poutsiaka, D.D.; King, A.J.; Strom, J.A.; Narayan, G.; Levey, A.S.; Dinarello, C.A. In vitro production of interleukin-1 receptor antagonists in chronic renal failure: CAPD and HD. Kidney Int. 1992, 42 (6), 1419-1424.
15. Powell, A.C.; Bland, L.A.; Oettinger, C.W.; McAllister, S.K.; Oliver, J.C.; Arduino, M.J.; Favero, M.S. Enhanced release of TNF alpha but not IL-1beta from uremic blood after endotoxin stimulation. Lymphokine Cytokine Res. 1991, 10 (5), 343-346.
16. Homes, C.; Evans, R.; Ross, D.; Frankamp, P. Plasma interleukin-1 and tumour necrosis factor levels during high flux dialysis with cellulose triacetate membranes (abstract). Kidney Int. 1990, 37, 301.
17. Powell, A.C.; Bland, L.; Oettinger, C.W. Plasma interleukin-1 beta and tumour necrosis factor alpha do not increase during unfavorable dialysis conditions (abstract). J. Am. Sol. Nephrol. 1990, 1, 373.
18. Mege, J.L.; Olmer, M.; Purgus, R.; Bertocchio, P.; Farnarier, C.; Kaplanski, S.; Capo, C.; Bongrand P. Hemodialysis membranes modulate chronically the production of TNF alpha, IL-1beta, and IL6. Nephrol. Dial. Transplant. 1991, 6 (11), 868-875.
19. Chollet-Martin, S.; Stamatakis, G.; Bailly, S.; Mery, J.P.; Gougerot-Pocidalo, M.A. Induction of tumor necrosis factor alpha during hemodialysis. Influence of membrane type. Clin. Exp. Immunol. 1991, 83 (2), 329-332.
20. Davenport, A.; Crabtree, J.; Androjna, C.; Will, E.J.; Davison, A.M. Tumour necosis factor does not increase during routine cuprophane haemodialysis in healthy well nourished patients. Nephrol. Dial. Transplant. 1991, 6 (6), 435-439.
21. Mandolfo, S.; Tetta, C.; David, S.; Gervasio, R.; Ognibene, D.; Wratten, M.L.; Tessore, E.; Imbasciati, E. In vitro and in vivo biocompatibility of substituted cellulose and synthetic membranes. Int. J. Artif. Organs 1997, 20 (11), 603-609.
22. McLaughlin, P.J.; Davies, H.M.; Aikawa, A. Tumour necrosis factor in normal plasma. Lancet 1990, 336 (8721), 1014-1015.
23. Haeffner-Cavaillon, N.; Cavaillon, J.M.; Ciancioni, C.; Bacle, F.; Delons, S.; Kazatchkine, M.D. In vivo induction of interleukin-1 during hemodialysis. Kidney Int. 1989, 35 (5), 1212-1218.
24. Dinarello, C.A. Cytokines: agents provocateurs in hemodialysis? Kidney Int. 1992, 41 (3), 683-694.
25. Zaoui, P.; Hakim, R.M. The effects of the dialysis membrane on cytokine release. J. Am. Soc. Nephrol. 1994, 4 (9), 1711-1718.
26. Goldfarb, S.; Golper, T. Proinflammatory cytokines and hemofiltration membranes. J. Am. Soc. Nephrol. 1994, 5 (2), 228-232.
27. Jorstad, S. Biocompatibility of different hemodialysis and plasmapheresis membranes. Blood Purif. 1987, 5 (2-3), 123-137.
28. Chanard, J.; Brunois, J.P.; Melin, J.P.; Lavaud, S.; Toupance, O. Long term results of dialysis therapy with a highly permeable membrane. Artif. Organs 1982, 6, 261-266.
29. Locatelli, F.; Mastrangelo, F.; Redaelli, B.; Ronco, C.; Marcelli, D.; LaGreca, G.; Orlandini, G. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int. 1996, 50 (4), 1293-1302.
30. Bergamo Collaborative Dialysis Study Group. Acute Intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Kidney Int. 1991, 40 (4), 714-719.
31. Skroeder, N.R.; Jacobson, S.H.; Lins, L.E.; Kjellstrand, C.M. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis. ASAIO Trans. 1990, 36, M637-M639.
32. Collins, D.M.; Lambert, M.B.; Tannenbaum, J.S.; Oliverio, M.; Schwab, S.J. Tolerance of hemodialysis: a randomized prospective trial of high flux versus conventional high efficiency hemodialysis. J. Am. Soc. Nephrol. 1993, 4 (2), 148-154.
33. Salem, M.; Ivanovich, P.T.; Ing, T.S.; Dougirdas, J.T. Adverse effects of dialyzers manifesting during the dialysis session. Nephrol. Dial. Transplant. 1994, 9 (suppl 2), 127-137.
34. Orofino, L.; Marcen, R.; Quereda, C.; Villefruela, J.J.; Sabater, J.; Matesanz, R.; Pascual, J.; Ortuno, J. Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate beneficial for all patients? Am. J. Nephrol. 1990, 10, 177-180.
35. Cappelli, G.; DiFelice, A.; Perrone, S.; Ballestri, M.; Bonucchi, D.; Savazzi, A.M.; Guffreda, A.; Lusvarghi E. Which level of cytokine production is critical in hemodialysis? Nephrol. Dial. Transplant. 1998, 13 (suppl 7), 55-60.